$ONCY last year January letter to shareholders, enrolment update for Goblet, Adlai advances second dose escalation Feb Giblet safety run in and announcement of Q4 conference call. This year nothing, not even the promise of final data since Dec 8th. Dec 1st/22 received FDA fast track for Panc. Aware final data was to be presented Dec 8th and Coffey was a no show. Bracelet finished patient enrolment 2Q which means last patient made it thru 16 week by end of June. Q3 “we continued retreating patients and monitored patients who came off of treatment due To progression, activities included Analyzing data on study’s primary endpoint if 16 week ORR and secondary endpoints of progression free survival and overall survival”that means Pfizer has had data for all of Q4 for 90 day exclusivity.Maybe Q1 is rest of big pharma chance to review data???? Maybe there is an offer from Pfizer with a 60day expiry??? This is killing me!!! Should be offer time. Going crazy!